Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Active, not recruiting · NCT03820141 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-20 | NCT03820141 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| The Methodist Hospital Research Institute | 124 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Houston Methodist Cancer Center | Houston | United States | 18 |